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Introduction: Although blinding is a methodologic safeguard to ensure obtaining comparability of groups in a
clinical trial, it is very difficult to maintain blinding from the beginning to the end of a study. The aim of the study
was to see how proper blinding of both participants and treatment providers from the planning phase of the study
to during the study affected the study outcomes.
Methods: We searched Medline, EMBASE, and Cochrane databases from inception to November 2011. The studies
included in this review were randomized controlled trials, with acute myocardial infarction (AMI) patients who
received percutaneous coronary intervention (PCI), intracoronary (IC) infusion of autologous bone marrow stem
cells (BMSCs), unselected BMSCs, 108 or more cell dose, and up to 6-month follow-up periods.
Results: The initial search identified 881 references, of which 17 references were eligible for inclusion. Six of 17
trials isolated cells directly from bone marrow by aspiration in the control group as well as in the BMSC group. Nine
of 17 trials underwent both cardiac catheterization and an identical injection procedure on the control group as
well as the BMSC group.
Compared with the control group, BMSC transplantation improved left ventricular ejection fraction (LVEF) by 2.51
(95% CI, 1.20 to 3.83; P = 0.0002; I2 = 75%) at 6 months. In the present results, the studies that did not perform
bone marrow aspiration in the control group showed significant improvement in LVEF by 3.81% (95% CI, 2.44 to
5.17), whereas no significant treatment effect was found in the studies in which the control group underwent bone
marrow aspiration, as indicated the LVEF change of −1.29% (95% CI, 4.15 to 1.58). The trials that did not conduct
catheterization on control subjects showed significant LVEF changes (4.45%; 95% CI, 2.48 to 6.43); however, those
with cardiac catheterization as a sham procedure on the control group did not show significant changes in LVEF at
6 months (0.92%; 95% CI, -0.61 to 2.44).
Conclusions: Unblinding might be overestimating the treatment effect. These findings suggest that randomized
controlled trials testing the efficacy of BMSC therapy should be appropriately designed and rigorously applied to
avoid bias.
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Bone marrow stem cell (BMSC) therapy has been sug-
gested to be safe for acute myocardial infarction (AMI)
patients. However, the efficacy of this approach for car-
diac repair remains controversial. A recent meta-analysis
showed that intracoronary mononuclear BMSC transfer
after AMI improved left ventricular ejection fraction
(LVEF) significantly (2.87%, 95% CI: 2.00-3.73) after a 1-
year follow-up [1]. However, these benefits were mixed,
and a very high degree of heterogeneity among studies has
been found. One of the reasons for this heterogeneity was
the differences among the study designs. There has been
debate regarding whether maintaining strict blindness in
stem cell clinical research study designs is appropriate, be-
cause too-rigorous study design entails ethical issues.
Some studies have maintained patient blindness in treat-
ment allocation through the bone marrow aspira-
tion of the control group with intracoronary infusion of
BMSCs or cell-free solution [2-7]. In addition, human
serum or plasma has been used to ensure that the color
and consistency of the solution should be matched with
that of the BMSC product. Some studies used cardiac
catheterization as a sham procedure in control group pa-
tients to maintain the blindness of heath care providers.
In these studies, a catheter was positioned in the stent seg-
ment, and the BMSC or a placebo was infused through
the catheter. With this method, the placebo and active
treatment could not be visually distinguished. In addition,
the healthcare provider who conducted the surgery was
not provided with any information on whether the pa-
tients belonged to the treatment or the control group, en-
suring rigorous double blinding.
The randomized controlled trial is regarded as the
strongest study design for assessing the benefit and harm
of healthcare interventions. However, randomization in
itself does not guarantee that trial results are valid.
Methodologic issues affecting the validity of randomized
controlled trials can occur both before and after assign-
ment. Pildal et al. (2008) underlined the importance of
allocation concealment to assess the intervention effects
in randomized controlled trials appropriately. Two thirds
of conclusions favoring an intervention would lose sup-
port if trials with unclear or inadequate allocation con-
cealment were excluded from the meta-analysis [8].
Blinding in a randomized controlled trial is the process
of masking treatment-allocation information. Unblinded
participants may be affected by biases in reporting their
symptoms, willingness to continue in the study, use of
other effective intervention methods, and placebo ef-
fects. Unblinded healthcare providers may also cause
biases through differential uses of other effective inter-
ventions, advice to patients as to whether to continue in
the trial, and influencing patient reporting of outcomes
[9,10].Although blinding is difficult to include in surgical tri-
als, it is important to consider the blinding status of the
groups when evaluating the methodology of any surgical
randomized controlled trial. It is unsurprising that many
studies have found that such trials can overestimate the
treatment effect by a substantial degree when compared
with adequately concealed randomized controlled trials
[11-13]. However, it is very difficult to maintain blinding
from the beginning to the end of a study while using a
consistent method. Once the blinding is broken, the
study results may be overestimated or underestimated
because of either study-participant or treatment-pro-
vider bias. An analysis of previously published studies on
therapeutic trials of treatments for AMI showed that
unblinded-randomized studies yield estimates of effect
about 16% larger compared with blinded-randomized
trials [11]. The randomized controlled trial continues to
be the best method for obtaining group comparability in
a clinical trial.
We conducted a systematic review and meta-analysis
to investigate the impact of blinding on outcomes after
intracoronary BMSCs in patients with AMI. The aim of
this meta-analysis was to examine how proper blinding
of both participants and treatment providers from the
planning phase of the study throughout the duration of
the study affected the intervention effects and study
outcomes.
Methods
Search strategy and study selection
We searched the Medline, EMBASE, and Cochrane da-
tabases from inception to November 2011 for studies of
BMSC transplantation in patients with AMI. The in-
cluded studies met the following criteria: (1) randomized
controlled trials, (2) AMI patients who received percu-
taneous coronary intervention (PCI), (3) intracoronary
infusion of autologous BMSCs, (4) a cell type of unse-
lected bone marrow stem cells, (5) a cell dose higher
than 108, and (6) studies that had a ≤6-month follow-up.
Exclusion criteria were (1) intracoronary infusion of
autologous BMSCs within 24 hours after primary PCI,
(2) patients with chronic myocardial infarction (CMI),
which continued at least more than 1 month after AMI,
(3) AMI patients who received coronary artery bypass
graft (CABG), and (4) studies published in languages
other than English. We restricted the included studies
by patient characteristics (AMI), cell type (unselected
BMSCs), cell dose (≥108), injection time (>24 hours after
PCI), and follow-up period (up to 6 months) to eliminate
heterogeneity due to these factors and to examine the
pure effects of rigorous study design in randomized con-
trolled trials. Statistical heterogeneity has been observed
and explored previously, and it has been suggested that
factors such as the timing of stem-cell infusion, the cell
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Figure 1 Flow diagram of studies included in this review.
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type, among others, are likely to contribute to statistical
heterogeneity [14-16].
Data extraction
Two investigators independently screened all titles and
abstracts to identify studies that met the inclusion cri-
teria and extracted relevant data, with divergences re-
solved by consensus. The details extracted were the
study and patient-population numbers and characte-
ristics, the type of cell dose, the route of delivery, the
time of injection, the nature of the intervention and the
comparator, and the follow-up period. The outcome
measures included changes in left ventricular ejection
fraction (LVEF), left ventricular end-systolic volume
(LVESV), and left ventricular end-diastolic volume
(LVEDV) from baseline to 6-month follow-up, with out-
come assessment by echocardiography, magnetic reson-
ance imaging (MRI), single-photon emission computed
tomography (SPECT), or left ventricular angiography.
When multiple imaging modalities were used, MRI data
were preferentially included in the analysis. Clinical trials
with multiple publications and sequential follow-up du-
rations or different outcomes were considered to be one
study.
Quality assessment
Two authors independently assessed the risk of bias for
each included study by using criteria based on the
Cochrane Handbook for Systematic Reviews of Interven-
tions, the principal components of which are sequence
generation, allocation concealment, blinding, incomplete
outcome data, and selective reporting bias [17]. Disag-
reements were resolved by discussion between the two
authors. Assessment of methodologic quality in terms of
blindness was assessed by three factors: bone marrow as-
piration, cardiac catheterization, and serum or plasma
infusion in both the treatment and control groups.
Statistical analyses
Outcome data were analyzed by using Review Manager
5.1, and presented as weighted mean differences and
95% confidence intervals. Data were pooled by use of
the DerSimonian-Laird random-effects model because of
the high degree of heterogeneity [18]. Heterogeneity was
analyzed with the I2 statistic, and heterogeneity was de-
fined as low (25% to 50%), moderate (50% to 75%), or
high (>75%). For studies that did not report the actual
change from baseline to 6-month follow-up, the change
in SD was calculated with a standardized formula used
to calculate changes in mean and standard deviation.
The extent to which the rigorous study-design effects of
maintaining blindness in both patients and healthcare
providers was associated with BMSC treatment effectswas examined by the univariate and multivariate meta-
regression model by using the PROC MIXED procedure
of SAS version 9.2 (SAS Institute Inc, Cary, NC, USA).Results
Search results
The initial search identified 881 references; 705 referen-
ces remained after duplicates were removed. Of these,
622 were nonrandomized studies, editorials, or reviews,
and 83 of these were examined in more detail. Seven-
teen of the 83 references were eligible for inclusion
[2-7,19-29] (Figure 1).Characteristics of the included studies
All trials compared unselected bone marrow stem cell
treatment with a control group with patients with AMI
and used PCI as a primary intervention. The presence of
AMI was diagnosed by cardiologists at each study site
by using such cardiac measurement tools as MRI, echo-
cardiography, and angiography. Of the 1,072 individuals,
607 were randomized into BMSC groups and 465 into
control groups aged between 18 and 80 years. All pa-
tients were recruited consecutively during the study pe-
riods. The sample size in each trial ranged from 10 to
204 participants. The follow-up duration was 6 months
in all but four trials: one was 3 months, and three were
4 months. The dosage of BMSCs ranged from 1 × 108 to
26.4 × 109. The time to BMSC transfer from the onset
of AMI ranged from 2 to 21 days. The baseline ejec-
tion fraction ranged from 32.4% to 59.6% (mean LVEF,
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summarized in Table 1.
To examine the effect of rigorous study design in
maintaining the blinding of both patients and healthcare
providers, we extracted data with respect to the follo-
wing three factors. First, to evaluate patient-treatment
blindness, we examined whether both the treatment and
the control groups underwent bone marrow aspiration.
Six of 17 trials isolated cells directly from bone marrow
by aspiration in both the control group and the BMSC
group. The second factor was whether cardiac catheteri-
zation was used as a sham procedure when surgeons
conducted the intracoronary administration. In nine of
17 trials, cardiac catheterization was used as a sham pro-
cedure in both the BMSC and control groups to main-
tain blindness. Third, we also looked at whether control
group patients were infused with a placebo such as their
own serum, plasma, or autologous erythrocytes without
BMSCs to ensure that healthcare providers remained
blinded to the study conditions. In nine of 17 trials, both
the BMSC and control groups underwent identical injec-
tion procedures that were visually indistinguishable from
the active treatment to maintain blindness (Table 2).Quality assessment
Study quality was assessed on the basis of randomiza-
tion, allocation concealment, blinding of outcome as-
sessment, and adequacy of follow-up. The overall quality
of the included trials was good (Table 3).Table 1 Characteristics of included studies
Study BMSC (n) Control (n) Cell d
Cao et al. [19] 41 45 5 × 1
Chang et al. [20] 20 20 1.5 ×
Grajeck et al. [21] 31 14 0.41 ×
Herbots et al. [2] 33 34 3.04 ×
Huikuri et al. [3] 36 36 4.02 ×
Meluzin et al. [22] 20 20 1 × 1
Penicka et al. [23] 17 10 26.4 ×
Piepoli et al. [24] 19 19 2.48 ×
Plewka et al. [25]) 40 20 1.44 ×
Schachinger et al. [4] 101 103 2.36 ×
Suarez de Lezo et al. [26] 10 10 9 × 1
Tendera et al. [27] 80 40 1.78 ×
Traverse et al. [5] 30 10 1.5 ×
Traverse et al. [6] 58 29 1.5 ×
Wohrle et al. [7] 29 13 3.81 ×
Wollert et al. [28] 30 30 24.6 ×
Yao et al. [29] 12 12 2.0 ×
BMSC bone marrow stem cell, LVEF left ventricular ejection fraction.Main findings
Compared with the control group, BMSC transplant-
ation improved LVEF by 2.51% (95% CI, 1.20 to 3.83;
P = 0.0002; I2 = 75%) at 6 months. BMSC transplan-
tation was similarly found to reduce LVESV by 4.98 ml
(95% CI, -7.65 to −2.31; P = 0.0003; I2 = 73%). A trend
of reduction in LVEDV was observed of 3.46 ml (95% CI,
-7.62 to 0.69; P = 0.1; I2 = 86%).
To examine the effect of rigorous study design on
maintaining blindness in both patients and healthcare
providers, we conducted separate analyses with respect
to the sham procedures, including bone marrow aspi-
ration and infusion of patients’ own serum for blinding
the patients and cardiac catheterization for blinding the
healthcare providers in the control group. The trials
were categorized into two groups according to whether
the studies used these procedures in the control group.
Six of 17 trials isolated cells directly from bone marrow
by aspiration and infused patients with their own serum
in the control group as well as the BMSC group. No sig-
nificant treatment effect was seen in six studies in which
the control group underwent bone marrow aspiration, as
indicated by an LVEF change of −1.29% (95% CI, −4.15
to 1.58). However, the rest of the 11 studies that did not
perform bone marrow aspiration in the control group
showed significant improvement in LVEF by 3.81%
(95% CI, 2.44 to 5.17) (Figure 2).
Nine of 17 trials included cardiac catheterization in
both the BMSC and the control group to maintain blind-
ness to treatment. Trials that used cardiac catheterizationose Injection time Baseline LVEF (%) Follow-up
08 7 days 38.8 6 mo
109 3 days 52.9 6 mo
109 4–5 days 55.5 6 mo
108 4–7 days 55.5 4 mo
108 2.5 days 56.5 6 mo
08 5–9 days 40.5 6 mo
108 4–11 days 39 4 mo
108 4 days 38.7 6 mo
108 7 days 34 6 mo
108 3–6 days 47.1 4 mo
08 7 days 38 3 mo
108 7 days 37 6 mo
108 4.5 days 38 6 mo
108 14–21 days 47 6 mo
108 5–7 days 59.6 6 mo
108 4.8 days 50.7 6 mo
108 3–7 days 32.4 6 mo
Table 2 Rigorousness of methodology
Study Bone marrow aspiration
in all patients
Comparator arm Cardiac catheterization
in all patients
Infused serum without cell
in the control group
Cao et al. [19] NO Heparinized saline YES NO
Chang et al. [20] NO No placebo NO NO
Grajeck et al. [21] NO No cell therapy YES NO
Herbots et al. [2] YES NS w/5% serum YES YES
Huikuri et al. [3] YES Serum YES YES
Meluzin et al. [22] NO Cell suspension media NO NO
Penicka et al. [23] NO Standardized medicine NO NO
Piepoli et al. [24] NO Optimized treatment only NO NO
Plewka et al. [25]) NO Standardized medicine NO NO
Schachinger et al. [4] YES Serum YES YES
Suarez de Lezo et al. [26] NO Heparinized saline NO NO
Tendera et al. [27] NO No cell therapy NO NO
Traverse et al. [5] YES Saline w/albumin YES YES
Traverse et al. [6] YES Saline w/albumin YES YES
Wohrle et al. [7] YES Erythrocyte YES YES
Wollert et al. [28] NO Medical treatment NO NO
Yao et al. [29] NO Heparinized saline YES NO
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LVEF at 6 months (0.92%; 95% CI, -0.61 to 2.44); however,
those without catheterization in control subjects showed
significant LVEF changes (4.45%; 95% CI, 2.48 to 6.43)
(Figure 3). Both LVESV and LVEDV reduction were alsoTable 3 Methodologic quality assessment of included studies
Study Randomization Al
con
Cao et al. [19] Y
Chang et al. [20] Y
Grajeck et al. [21] Y
Herbots et al. [2] Y
Huikuri et al. [3] Y
Meluzin et al. [22] U
Penicka et al. [23] U
Piepoli et al. [24] N
Plewka et al. [25]) U
Schachinger et al. [4] Y
Suarez de Lezo et al. [26] Y
Tendera et al. [27] Y
Traverse et al. [5] Y
Traverse et al. [6] Y
Wohrle et al. [7] Y
Wollert et al. [28] Y
Yao et al. [29] Y
Y low risk of bias, U unclear; N high risk of bias.overestimated, according to the rigorousness of the study
design (Table 4).
We conducted meta-regression analyses to explore the
source of heterogeneity. The results showed that ri-






















Figure 2 Forest plot of mean difference in LVEF with or without bone marrow aspiration.
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associated with the BMSC treatment effects, even after
being controlled for the effects of randomization, alloca-
tion concealment, cell dose, injection time, and baseline
LVEF (Table 5).
Discussion
The present meta-analysis included 17 RCTs in which
BMSC treatment was compared with a control group.
The results demonstrated that, at 6 months, BMSC
treatment leads to a 2.51% improvement in LVEF, a
4.98-ml reduction in LVESV, and a 3.46-ml reduction in
LVEDV. Similar results were obtained in recent meta-
analyses [30,31]. Taken together, BMSC treatment
improved LVEF outcome at 6 months.
We stress some important issues concerning rigorous
study design in randomized controlled trials. All of the
RCTs in the present analysis conducted random alloca-
tion to treatment and control groups. However, some
researchers made an effort to maintain blindness to pa-
tients as well as healthcare providers in regard to group
allocation, whereas others did not. Clinical trials of stem
cell therapy should be strictly designed, as it is verydifficult to maintain blinding throughout the entire
research period, even when research is designed with
double-blind controlled trials [8]. We considered two
procedures that are performed to maintain the blindness
of treatment allocation to both patients and healthcare
providers. First, bone marrow is harvested in all patients,
including the control group, under full anesthesia just
before surgery to ensure that the characteristics of the
BMSC suspension do not differ significantly between the
two groups [2-7]. Second, patients are returned to
cardiac catheterization after bone marrow aspiration to
ensure identical injection procedures in all patients. It is
assumed that using autologous erythrocytes or patients’
own serum or plasma in the placebo preparation ensures
double blindness. In the present results, no significant
treatment effect was found in studies in which the
control group underwent bone marrow aspiration, as in-
dicated by the LVEF change of −1.29% (95% CI, −4.15 to
1.58), whereas studies that did not perform bone
marrow aspiration in the control group showed signifi-
cant improvement in LVEF by 3.81% (95% CI, 2.44 to
5.17). The intervention effect might therefore be
overestimated because of the study design. Several trials
Figure 3 Forest plot of mean differences in LVEF with or without cardiac catheterization.
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content of the syringes could be easily distinguished be-
tween the active treatment and the placebo. It is import-
ant that BMSCs were harvested in all patients, including
the control group, under full anesthesia just before sur-
gery, to guarantee that the characteristics of the BMSC
suspension did not differ significantly between groups.
Nine of 17 trials implemented identical cardiac cathe-
terization injection procedures after bone marrowTable 4 Comparing the difference LVESV and LVEDV with
or without bone marrow aspiration and cardiac
catheterization in the control group
LVESV LVEDV
WMD (95% CI) WMD (95% CI)
BM aspiration in the
control group
Yes −2.77 (−6.27 to 0.74) −1.88 (−9.80 to 6.04)
No −6.39 (−10.02 to −2.77) −4.54 (−9.87 to 0.79)
Cardiac catheterization
in the control group
Yes −3.72 (−6.35 to −1.09) −2.40 (−7.75 to 2.94)
No −7.31 (−13.45 to −1.17) −4.97 (−11.52 to 1.57)aspiration in both the BMSC and control groups to
maintain study blindness [2-7,19,21]. The surgeon was
unaware whether cells or only saline was being injected.
Trials that conducted cardiac catheterization as a sham
procedure in the control group did not show significant
changes in LVEF at 6 months (0.92%; 95% CI, -0.61 to
2.44); however, those without catheterization of control
subjects showed significant LVEF changes (4.45%; 95% CI,
2.48 to 6.43).
One of the major differences of this study from other
preexisting studies is that only conditions known to be
effective in bias-minimized RCT studies were selected to
evaluate how the rigorousness of method affected treat-
ment effects. All included studies included PCI before
the infusion of BMSC treatment or placebo. We inclu-
ded only trials in which the cell dose was higher than
108. Previous trials determined that the use of 108 or
more injected cells shows improved outcomes in BMSC-
treated patients [15,30]. The mean change in LVEF was
statistically significant in favor of administering BMSCs
in studies using higher doses of BMSCs. These results
suggest that significant effects on LVEF may be achieved
only when the infusing doses are higher than 108 BMSCs.
The route of BMSC delivery was intracoronary artery
Table 5 Univariate and multivariate meta-regression analyses of BMSC treatment effects
Study characteristics Univariate analysis Multivariate analysisc
Mean difference (95% CI) P Mean difference (95% CI) P
Bone marrow aspirationa −3.27 (−3.89 to −2.65) <0.0001 −6.62 (−9.65 to −3.59) 0.0003
Catheterizationb −0.54 (−3.57 to 2.50) 0.688 −5.55 (−9.35 to −1.76) 0.0071
Effects of study quality
Randomization 1.23 (−2.62 to 5.08) 0.474 −2.62 (−6.16 to 0.92) 0.135
Allocation concealment 0.43 (−3.54 to 4.39) 0.807 −0.05 (−4.69 to 4.59) 0.982
Effects of study characteristics
Cell dose 2.23 (−0.10 to 4.55) 0.059 1.45 (−3.42 to 6.32) 0.535
Injection time 2.10 (−0.15 to 4.35) 0.065 1.46 (−3.48 to 6.39) 0.538
Baseline LVEF 1.69 (−0.45 to 3.84) 0.114 3.40 (−1.66 to 8.46) 0.172
aBone marrow aspiration in the control group. bCatheterization in the control group. cAdjusted by randomization, allocation concealment, cell dose, injection time,
and baseline LVEF.
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present meta-analysis included only AMI patients. All
included trials reported up to 6 months of short-term
follow-up data to demonstrate the effects of rigorous
study design.
We excluded whether the BMSCs were administered
within 24 hours after primary PCI, because it was previ-
ously shown that the timing of cell transfer does not
have a BMSC treatment effect in AMI patients [31,32].
A larger randomized study suggested that BMSCs should
ideally be administrated more than 4 days after STEMI
to obtain the best benefit from this therapy [4]. In a sub-
group analysis, the REPAIR-AMI Trial found that the
most favorable effects on LV function were observed
with BMSC delivery on days 5 to 7 after MI [4].
We chose the studies to be included based on study
design, route of delivery, cell type, cell dose, timing of
injection, and follow-up duration to reduce heterogen-
eity and to estimate the effect of rigorous study design
in randomized controlled trials. Heterogeneity was re-
duced from between 85% and 98% to 75% in the present
study. When only rigorously designed studies were in-
cluded in the analysis, heterogeneity was further reduced
to 60%. Meta-regression analyses, exploring the source
of heterogeneity, indicated that the treatment effects
seen were associated with rigorous study designs. These
findings were similar to those of the subgroup analyses.
Design rigorousness seemed to explain the heterogeneity
in the studies; however, a considerable degree of hetero-
geneity was still observed among the included trials.
This might be due to differences in patient severity at
baseline, the timing of infusions, or the duration of
follow-up between studies.
Conclusions
These findings suggest that randomized controlled trials
testing the effectiveness of BMSC therapy should beappropriately designed and rigorously applied to avoid
bias. Blinding might overestimate the treatment effect. If
properly designed, conducted, and interpreted, study
results are likely to make a substantial impact on the
outcomes of patients.
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